November 14, 2007 - Æterna Zentaris Inc. (Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy and oncology, announced the completion of patient recruitment for the Company’s European multi-center Phase 2 trial in non-small cell lung cancer (NSCLC) with its novel, first-in-class, oral signal transduction inhibitor, perifosine. This randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of a 150 mg daily dose of perifosine when combined with radiotherapy in 160 patients with inoperable Stage III NSCLC... Æterna Zentaris' Press Release -
Nov 19, 2007
Æterna Zentaris, Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
November 14, 2007 - Æterna Zentaris Inc. (Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy and oncology, announced the completion of patient recruitment for the Company’s European multi-center Phase 2 trial in non-small cell lung cancer (NSCLC) with its novel, first-in-class, oral signal transduction inhibitor, perifosine. This randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of a 150 mg daily dose of perifosine when combined with radiotherapy in 160 patients with inoperable Stage III NSCLC... Æterna Zentaris' Press Release -
